VMD-928

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
82 patients (estimated)
Sponsors
VM Oncology, LLC
Tags
Tyrosine Kinase (TK) Inhibitor
Trial Type
Treatment
Last Update
2 months ago
SparkCures ID
1401
NCT Identifier
NCT03556228

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(831) 888-0898

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.